Literature DB >> 33734329

Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.

Ken-Hong Lim1,2,3, Jo-Ning Wu3, To-Yu Huang3, Jie-Yang Jhuang4, Yu-Cheng Chang1,2,3, Huan-Chau Lin1,3, Yi-Hao Chiang1,3, Ying-Wen Su1,2,3, Caleb Gon-Shen Chen1,2,3,5,6, Yi-Fang Chang1,2,3, Johnson Lin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33734329      PMCID： PMC7993095          DOI： 10.1182/bloodadvances.2020003980

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  18 in total

1.  Comprehensive mutational profiling in advanced systemic mastocytosis.

Authors:  Juliana Schwaab; Susanne Schnittger; Karl Sotlar; Christoph Walz; Alice Fabarius; Markus Pfirrmann; Alexander Kohlmann; Vera Grossmann; Manja Meggendorfer; Hans-Peter Horny; Peter Valent; Mohamad Jawhar; Martina Teichmann; Georgia Metzgeroth; Philipp Erben; Thomas Ernst; Andreas Hochhaus; Torsten Haferlach; Wolf-Karsten Hofmann; Nicholas C P Cross; Andreas Reiter
Journal:  Blood       Date:  2013-08-19       Impact factor: 22.113

2.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

Authors:  Jason Gotlib; Hanneke C Kluin-Nelemans; Tracy I George; Cem Akin; Karl Sotlar; Olivier Hermine; Farrukh T Awan; Elizabeth Hexner; Michael J Mauro; David W Sternberg; Matthieu Villeneuve; Alice Huntsman Labed; Eric J Stanek; Karin Hartmann; Hans-Peter Horny; Peter Valent; Andreas Reiter
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

3.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

4.  Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Authors:  Animesh Pardanani; Sahrish Shah; Francesco Mannelli; Yoseph C Elala; Paola Guglielmelli; Terra L Lasho; Mrinal M Patnaik; Naseema Gangat; Rhett P Ketterling; Kaaren K Reichard; Curtis A Hanson; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood Adv       Date:  2018-11-13

5.  Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.

Authors:  Thomas Kristensen; Hanne Vestergaard; Carsten Bindslev-Jensen; Michael Boe Møller; Sigurd Broesby-Olsen
Journal:  Am J Hematol       Date:  2014-02-21       Impact factor: 10.047

Review 6.  New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.

Authors:  Andreas Reiter; Tracy I George; Jason Gotlib
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

7.  Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

Authors:  D J DeAngelo; T I George; A Linder; C Langford; C Perkins; J Ma; P Westervelt; J D Merker; C Berube; S Coutre; M Liedtke; B Medeiros; D Sternberg; C Dutreix; P-A Ruffie; C Corless; T J Graubert; J Gotlib
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

Review 8.  Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Authors:  Molly M Gallogly; Hillard M Lazarus; Brenda W Cooper
Journal:  Ther Adv Hematol       Date:  2017-08-19

9.  Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.

Authors:  Stanley Chun-Wei Lee; Heidi Dvinge; Eunhee Kim; Hana Cho; Jean-Baptiste Micol; Young Rock Chung; Benjamin H Durham; Akihide Yoshimi; Young Joon Kim; Michael Thomas; Camille Lobry; Chun-Wei Chen; Alessandro Pastore; Justin Taylor; Xujun Wang; Andrei Krivtsov; Scott A Armstrong; James Palacino; Silvia Buonamici; Peter G Smith; Robert K Bradley; Omar Abdel-Wahab
Journal:  Nat Med       Date:  2016-05-02       Impact factor: 53.440

Review 10.  SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms.

Authors:  Katherine Linder; Chaitanya Iragavarapu; Amandeep Aujla; Michael Karass; Delong Liu
Journal:  Biomark Res       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.